Zinc Acetate for Foot Psoriasis
Oral zinc acetate is not recommended for treating foot psoriasis, as oral zinc supplementation has not been shown to improve psoriasis outcomes. 1
Evidence Against Oral Zinc for Psoriasis
The American Academy of Dermatology-National Psoriasis Foundation joint guidelines explicitly state that oral zinc supplementation did not independently improve psoriasis. 1 This recommendation is supported by multiple controlled trials:
A double-blind controlled study of 25 patients with chronic plaque psoriasis found no statistically significant differences in PASI scores between zinc-treated and placebo groups over 12 weeks, providing no evidence of benefit from zinc supplementation. 2
A systematic review examining zinc supplementation across inflammatory skin conditions found that the single study on psoriasis showed no significant benefit of zinc treatment on disease outcome. 3
While one study showed zinc sulfate could normalize neutrophil chemotaxis in psoriasis patients, it had little or no effect on the actual clinical course of the disease, suggesting neutrophils play only a secondary role in pathogenesis. 4
FDA-Approved Indication for Zinc Acetate
Zinc acetate is FDA-approved exclusively for Wilson's disease (hepatolenticular degeneration), not for any dermatologic condition. 5 The mechanism—blocking intestinal copper absorption by inducing metallothionein in enterocytes—is irrelevant to psoriasis pathophysiology. 5
Topical Zinc Formulations: Limited Evidence
While oral zinc fails, some topical zinc preparations show modest benefit for localized psoriasis:
Topical zinc pyrithione 0.25% in emollient cream reduced mean PASI scores from 3.4 to 0.9 over 3 months in patients with <10% body surface area involvement, significantly better than emollient alone. 6
A supramolecular active zinc hair conditioner showed a 39% disease control rate for scalp psoriasis at 4 weeks, non-inferior to calcipotriol ointment (37%) and superior to placebo (25%). 7
However, topical zinc preparations are not standard first-line therapy and lack robust comparative data against established topical treatments like corticosteroids or vitamin D analogues.
Safety Concerns
Oral zinc at high doses with prolonged use causes copper deficiency, anemia, leukopenia, neutropenia, and gastrointestinal ulcers. 1
Zinc oxide nanoparticles in topical formulations may actually delay healing of psoriasis-like lesions by promoting inflammation and keratinocyte apoptosis through NFκB activation and cysteine deficiency. 8
Recommended Approach for Foot Psoriasis
For localized foot psoriasis (<3% body surface area):
Use topical corticosteroids or vitamin D analogues as first-line therapy, not zinc products. 9
Consider topical zinc pyrithione only as adjunctive therapy if standard treatments are insufficient and the patient specifically requests natural alternatives. 6
For moderate-to-severe disease (≥3% body surface area):